Toronto - Delayed Quote CAD

Profound Medical Corp. (PRN.TO)

7.34

+0.64

+(9.55%)

At close: May 2 at 3:59:30 PM EDT

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre. The

GlobeNewswire 2 days ago

PROF
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapie

GlobeNewswire 4 days ago

PROF
Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the

GlobeNewswire 16 days ago

PROF
With 56% institutional ownership, Profound Medical Corp. (TSE:PRN) is a favorite amongst the big guns

Key Insights Institutions' substantial holdings in Profound Medical implies that they have significant influence over...

Simply Wall St. 16 days ago

PROF
Profound Medical AUA 2025 Investor Event Agenda

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting. The event will be held at the Wa

GlobeNewswire 18 days ago

PROF
Save the Date: Profound Medical to Host Investor Event at AUA 2025

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host a hybrid (in-person and virtual) investor event on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting in Las Vegas, NV, from 3:30 p.m. to 5:00 p.m. Pacific Time (6:30 p.m. to 8:00 p.m.

GlobeNewswire last month

PROF
Insider Spends US$144k Buying More Shares In Profound Medical

Potential Profound Medical Corp. ( TSE:PRN ) shareholders may wish to note that the Chairman of the Board & CEO, Arun...

Simply Wall St. last month

PROF
Profound Medical Corp (PROF) Q4 2024 Earnings Call Highlights: Record Revenue and Improved ...

Profound Medical Corp (PROF) reports a 108% revenue growth and a significant reduction in net loss, while navigating challenges in site expansion and reimbursement strategies.

GuruFocus.com last month

PROF
Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.

GlobeNewswire last month

PROF
Profound Medical (TSE:PRN) adds CA$31m to market cap in the past 7 days, though investors from five years ago are still down 39%

Profound Medical Corp. ( TSE:PRN ) shareholders should be happy to see the share price up 11% in the last week. But...

Simply Wall St. 2 months ago

PROF
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business dev

GlobeNewswire 2 months ago

PROF
Profound Medical Corp.'s (TSE:PRN) Profit Outlook

We feel now is a pretty good time to analyse Profound Medical Corp.'s ( TSE:PRN ) business as it appears the company...

Simply Wall St. 3 months ago

PROF
Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th

TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its scheduled presentation time at the 43rd Annual J.P. Morgan Healthcare Conference has been changed to 9:00 a.m. Pacific Time on Thursday, January 16, 2025. The presentation will be broadcast live and archived on t

GlobeNewswire 3 months ago

PROF
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision

GlobeNewswire 3 months ago

PROF
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 11:15 a.m. Pacific Time in San Francisco, CA. The presentation will be

GlobeNewswire 3 months ago

PROF
Chairman of the Board & CEO of Profound Medical Picks Up 3.7% More Stock

Investors who take an interest in Profound Medical Corp. ( TSE:PRN ) should definitely note that the Chairman of the...

Simply Wall St. 4 months ago

PROF
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 5,366,705 Common Shares being issued today for aggregate gross proceeds, before d

GlobeNewswire 4 months ago

PROF
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 4,666,700 common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The gross proceeds of the Offering to Profound, before de

GlobeNewswire 4 months ago

PROF
Profound Medical Announces Proposed Public Offering of Common Shares

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (the “Common Shares”) in an underwritten public offering (the “Offering”). In addition, Profound expects to grant the underwriters of the Offering a 30-day option to purchase up to an

GlobeNewswire 4 months ago

PROF
Profound Medical, Siemens Healthineers enter co-sales, co-marketing agreement

Profound Medical (PROF) entered into a definitive co-sales and co-marketing agreement with Siemens Healthineers (SIEGY) pursuant to which the companies will commercialize a new MRI-guided prostate therapy solution which combines Profound’s TULSA-PRO system and consumables with Siemens Healthineers’ Magnetom Free.Max magnetic resonance scanner. Subject to the completion of the compatibility process of TULSA-PRO and Magnetom Free.Max, the companies currently expect to initiate sales of the total p

TipRanks 4 months ago

PROF

SIEGY

SMAWF

Performance Overview

Return	PRN.TO	S&P/TSX Composite index (^GSPTSE)
YTD	-26.53%	+1.67%
1-Year	-26.67%	+14.70%
3-Year	-25.25%	+20.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Profound Medical Corp. (PRN.TO)

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow

With 56% institutional ownership, Profound Medical Corp. (TSE:PRN) is a favorite amongst the big guns

Profound Medical AUA 2025 Investor Event Agenda

Save the Date: Profound Medical to Host Investor Event at AUA 2025

Insider Spends US$144k Buying More Shares In Profound Medical

Profound Medical Corp (PROF) Q4 2024 Earnings Call Highlights: Record Revenue and Improved ...

Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

Profound Medical (TSE:PRN) adds CA$31m to market cap in the past 7 days, though investors from five years ago are still down 39%

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Profound Medical Corp.'s (TSE:PRN) Profit Outlook

Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Chairman of the Board & CEO of Profound Medical Picks Up 3.7% More Stock

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Proposed Public Offering of Common Shares

Profound Medical, Siemens Healthineers enter co-sales, co-marketing agreement

Performance Overview